Bristol Myers Squibb (BMY) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Bristol Myers Squibb, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track BMY live on Mooboard →
This week1
- Sep 30, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986449 · Phase 1 / Phase 2 · Advanced Solid TumorsNCT05888831: A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
Next 30 days5
- Oct 5, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutKarXT · Phase 3 · Psychosis Associated With Alzheimer's DiseaseNCT05511363: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1). Primary completion 2026-10-05 (estimated); status RECRUITING.
- Oct 6, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986278 · Phase 3 · Idiopathic Pulmonary FibrosisNCT06003426: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis. Primary completion 2026-10-06 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 12, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutCC-92480 · Phase 1 / Phase 2 · Multiple MyelomaNCT05372354: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma. Primary completion 2026-10-12 (estimated); status RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutDeucravacitinib · Phase 3 · Systemic Lupus ErythematosusNCT05617677: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutDeucravacitinib · Phase 3 · Systemic Lupus ErythematosusNCT05620407: A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus. Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
31–90 days6
- Nov 1, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutKarXT · Phase 3 · Bipolar-I Disorder With Mania or Mania With Mixed FeaturesNCT06951698: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder. Primary completion 2026-11-01 (estimated); status RECRUITING.
- Nov 2, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutKarXT · Phase 3 · Bipolar Disorder Type I With Mania or Mania With Mixed FeaturesNCT06951711: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2). Primary completion 2026-11-02 (estimated); status RECRUITING.
- Nov 18, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutDeucravacitinib · Phase 3 · Sjögren's SyndromeNCT05946941: A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome. Primary completion 2026-11-18 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 24, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutKarXT · Phase 3 · Alzheimer DiseaseNCT06585787: A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4). Primary completion 2026-11-24 (estimated); status RECRUITING.
- Dec 9, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutKarXT · Phase 3 · Psychosis Associated With Alzheimer's DiseaseNCT06126224: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2). Primary completion 2026-12-09 (estimated); status RECRUITING.
- Dec 14, 2026ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986435 · Phase 2 · Heart FailureNCT06122779: Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF). Primary completion 2026-12-14 (estimated); status ACTIVE_NOT_RECRUITING.
Later13
- Jan 6, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986470 · Phase 1 / Phase 2 · Anemia, Sickle Cell; Healthy VolunteersNCT06481306: A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease. Primary completion 2027-01-06 (estimated); status RECRUITING.
- Jan 30, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986369 · Phase 1 / Phase 2 · Relapsed or Refractory T-cell LymphomasNCT06035497: A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3). Primary completion 2027-01-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 5, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutNivolumab · Phase 2 · Non-Small Cell Lung CancerNCT06946797: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC). Primary completion 2027-02-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 16, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutRepotrectinib · Phase 3 · Carcinoma, Non-Small-Cell LungNCT06140836: A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3). Primary completion 2027-02-16 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 11, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutNivolumab · Phase 3 · Renal Cell CarcinomaNCT03873402: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer. Primary completion 2027-03-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 18, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986446 · Phase 2 · Alzheimer Disease, Early OnsetNCT06268886: Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease. Primary completion 2027-03-18 (estimated); status ACTIVE_NOT_RECRUITING.
- Jun 28, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutXanomeline/Trospium Chloride · Phase 3 · Mania; Bipolar DisorderNCT07140913: A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine. Primary completion 2027-06-28 (estimated); status RECRUITING.
- Jul 16, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutLuspatercept · Phase 2 · AnemiaNCT05664737: A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia. Primary completion 2027-07-16 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 7, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutKarXT · Phase 3 · Psychosis Associated With Alzheimer's DiseaseNCT05980949: Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3). Primary completion 2027-09-07 (estimated); status RECRUITING.
- Oct 28, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986458 · Phase 1 / Phase 2 · Relapsed/Refractory Non-Hodgkin LymphomaNCT06090539: A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas. Primary completion 2027-10-28 (estimated); status RECRUITING.
- Dec 27, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986278 · Phase 3 · Progressive Pulmonary FibrosisNCT06025578: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. Primary completion 2027-12-27 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 30, 2027ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutBMS-986393 · Phase 3 · Relapsed or Refractory Multiple Myeloma (RRMM)NCT06615479: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2). Primary completion 2027-12-30 (estimated); status RECRUITING.
- Jan 9, 2028ClinicalTrials.gov ↗Bristol Myers Squibb(BMY)Phase 2/3 readoutRituximab · Phase 2 · LymphomaNCT07015242: A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma. Primary completion 2028-01-09 (estimated); status RECRUITING.
How Bristol Myers Squibb has moved — past-year price reactions
How binary is BMY? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
1%
0
27.6%
249
Largest single-day moves
- +7.1%2025-10-30no matched headline
- +5.6%2025-12-03no matched headline
- +5.2%2026-04-30no matched headline
- +5.2%2025-10-01no matched headline
- +4.2%2026-01-07no matched headline
- +4.1%2026-02-06no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
Bristol Myers Squibb — active clinical pipeline
Bristol Myers Squibb's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
63 assets114 programsPh1 26Ph2 31Ph3 50· 7 post-marketing (Ph4)
AreasOncologyAutoimmuneNeuroscienceCardiovascularOther
KarXTNeuroscience
Phase 1
Phase 3
Alzheimer Disease (3)Alzheimer's DiseaseBipolar Disorder Type I With ManiaBipolar Disorder Type I With Mania or Mania With Mixed FeaturesBipolar-I Disorder With Mania or Mania With Mixed FeaturesIrritability Associated With Autism Spectrum Disorder (2)Psychosis Associated With Alzheimer's Disease (3)Schizophrenia (3)
NivolumabOncology · PD-1
DeucravacitinibAutoimmune · TYK2
Phase 2
PumitamigOncology
Phase 2
BMS-986504Oncology
BMS-986278Other
Iza-brenOncology
Xanomeline/Trospium Chloride CapsuleNeuroscience
Phase 1
OzanimodAutoimmune · S1PR5
Xanomeline/Trospium ChlorideNeuroscience
Phase 3
AbataceptAutoimmune · CD80/86
Phase 3
BelataceptOther · CD80/86
Phase 3
BMS-986489 (Atigotatug+Nivolumab)Oncology
IberdomideOncology · cereblon
Phase 3
IpilimumabOncology
Phase 3
MavacamtenCardiovascular · cardiac myosin
Phase 3
MezigdomideOncology
Nivolumab + RelatlimabOncology
Phase 3
Nivolumab and rHuPH20Oncology
RelatlimabOncology · LAG-3
Phase 3
RepotrectinibOncology · CD74/TRK/ROS1
CC-97540Autoimmune
Arlocabtagene AutoleucelOncology
Phase 2
BMS-986340Oncology
Phase 2
BMS-986369Oncology
BMS-986446Neuroscience
BMS-986449Oncology
Phase 2
BMS-986458Oncology
BMS-986482Oncology
Phase 2
BMS-986490Oncology
Phase 2
BMS-986507Oncology
Phase 2
BMS-986511Neuroscience
Phase 2
BMS-986517Oncology
Phase 2
BMS-986523Oncology
Phase 2
BMS-986528Autoimmune
Phase 2
CC-486Oncology
Phase 2
CC-92480Oncology
Phase 2
FedratinibOncology · FLT3/JAK2
Phase 2
RituximabOncology · CD20
Phase 2
BMS-985521Other
Phase 1
BMS-986453Oncology
BMS-986454Autoimmune
Phase 1
BMS-986460Oncology
BMS-986463Oncology
BMS-986484Oncology
Phase 1
BMS-986488Oncology
Phase 1
BMS-986489Oncology
Phase 1
BMS-986500Oncology
Phase 1
BMS-986506Oncology
Phase 1
BMS-986515Autoimmune
BMS-986521Other
Phase 1
BMS-986533Other
Phase 1
CC-122Oncology
Phase 1
GolcadomideOther
Phase 1
MRTX1719Other
Phase 1
Xanomeline/ Trospium ChlorideOther
Phase 1
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built
See the full biopharma catalyst calendar across all covered companies.